Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review - Takeaways - MDSpire

Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review

  • By

  • Sha Su

  • Yu Teng

  • Shaojiao Liu

  • Lei Wang

  • Mingjing Zhao

  • June 18, 2026

  • 0 min

Share

  • 1

    Ischemic heart disease (IHD) affects approximately 254 million people globally, leading to nearly 9 million deaths in 2021.

  • 2

    Engineered extracellular vesicles (EVs) show promise in IHD treatment due to their ability to carry therapeutic molecules and target specific tissues.

  • 3

    Modification methods for engineered EVs include internal loading, surface modification, and combination with biotechnological materials.

  • 4

    Engineered EVs can improve cardiac function by alleviating fibrosis, inhibiting inflammation, promoting angiogenesis, and enhancing metabolism.

  • 5

    The review provides a framework for optimizing engineered EVs, emphasizing their potential for multi-targeted synergy and clinical application in IHD.

Original Source(s)

Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review

  • by Sha Su, Yu Teng, Shaojiao Liu, Lei Wang, Mingjing Zhao

  • June 18, 2026

Related Content

Most Decline Proactive Care Coordination

"Lack of effective communication across physicians is a health system problem."

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.